Related Experiment Video
Updated: May 31, 2026
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
EGFR expression in advanced head and neck cutaneous squamous cell carcinoma
Larissa Sweeny1, Nichole R Dean, J Scott Magnuson
1Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Head & Neck
|July 9, 2011
Summary
Epidermal growth factor receptor (EGFR) expression is common in advanced head and neck cutaneous squamous cell carcinoma (SCC). However, EGFR overexpression did not correlate with poorer survival or increased metastasis in this patient group.
Area of Science:
- Oncology
- Dermatology
- Head and Neck Cancer Research
Background:
- The role of epidermal growth factor receptor (EGFR) in advanced cutaneous squamous cell carcinoma (SCC) of the head and neck is not well-defined.
- Understanding EGFR's significance is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the correlation between EGFR expression and clinical outcomes in patients with advanced head and neck cutaneous SCC.
- To determine if EGFR overexpression is associated with aggressive disease characteristics or reduced survival.
Main Methods:
- Retrospective review of 56 patients diagnosed with stage III or IV cutaneous SCC of the head and neck.
- Analysis of EGFR expression in primary tumors and regional metastatic lesions.
- Correlation of EGFR expression with overall survival and clinicopathologic features.
Main Results:
- EGFR was overexpressed in over half of primary tumors (56%) and regional metastases (58%).
- No significant correlation was found between EGFR expression and overall survival (p = .47).
- EGFR expression did not correlate with the presence or extent of regional (p = .74) or distant metastasis (p = .56).
Conclusions:
- Upregulation of EGFR is not associated with poor survival in advanced head and neck cutaneous SCC.
- EGFR expression does not appear to be a reliable biomarker for aggressive disease in this context.
